Is Allergan about to get its groove back?

Shares of the Botox maker have been under pressure for the past several months after the company said that Darpin, a highly anticipated drug, had encountered delays.

By MSN Money Partner Aug 2, 2013 12:24PM

File photo of a bottle of Botox made by Allergan Inc. (© Damian Dovarganes/AP Photo)CNBCBy Lee Brodie

 

With the stock down sharply since April, is Allergan (AGN) finally ready to rebound?

 

That's a pressing question for Jim Cramer.

 

"I've liked this stock for a long time not only for its breast implants, wrinkle-removers, and eyelash enlargers, but also for its more traditional drug business focused on eye care and migraines," Cramer said.

 

In April 2012, Cramer called Allergan "a fabulous growth stock."

 

But even the most fabulous stocks can hit a rough patch.

 

Shares have been under pressure for the past several months after Allergan said that Darpin, a highly anticipated drug, had encountered delays.

 

"We also learned that Allergan's second biggest drug, Restasis for dry eye, might face generic competition sooner than expected," Cramer said.

 

Developments sent investors running for the exits.

 

Cramer, however, can't help but wonder if sellers will regret their decision. The latest earnings report suggests strength not weakness.

 

Allergan reported a second-quarter profit of $359.9 million, or $1.19 a share, up from $295.4 million, or 96 cents a share, a year earlier. Revenue increased 10% to $1.6 billion.

 

Meanwhile, Allergan's medical device segment posted sales of $229.3 million during the quarter, up 7.4% compared with Q2 2012; sales for its breast implant business were up 5.5% to $106.8 million and sales for its facial aesthetics business were $122.5 million, up 9.1%.

 

Cramer thinks the strong earnings may be just an early glimpse of all the good things to come.

 

He reminded that "Allergan throws off a lot of cash and it still has consistent earnings per share growth in the mid-teens."

 

In the past Cramer has cited a slew of other positive catalysts ranging from the company's clear growth path and international expansion plans to its strong balance sheet and shareholder friendly initiatives.

 

All told, Cramer remains bullish. If anything, he believes the weakness is an opportunity. "I'm a buyer," Cramer said.

 

More from CNBC

0Comments

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

STOCK SCOUTER

StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

125
125 rated 1
264
264 rated 2
485
485 rated 3
679
679 rated 4
640
640 rated 5
617
617 rated 6
632
632 rated 7
493
493 rated 8
276
276 rated 9
153
153 rated 10
12345678910

Top Picks

SYMBOLNAMERATING
TAT&T Inc9
VZVERIZON COMMUNICATIONS8
CTLCENTURYLINK Inc8
EXCEXELON CORPORATION8
AAPLAPPLE Inc10
More

VIDEO ON MSN MONEY

ABOUT

Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.